According to the literature survey, the prevalence of chronic spontaneous urticaria (CSU) was estimated to be 0.75% to 1.02?ses within adults, however, ~ 30% to 55% of patients are diagnosed and symptomatic. 10% to 15% of patients are being diagnosed with mild, 29% to 31% of patients are being diagnosed with moderate and 27% to 29% patients are being diagnosed with a severe type of CSU. An estimated 10% to 12% of adults have experienced at least 1 episode of CSU at some time in their lives.
Comprehensive insight on patient segmentation based on age, sex, disease conditions, Severity (Mild, Moderate & Severe), patient Characteristics, Signs & Symptoms, Clinical Manifestations, Treatment types has been provided in the epidemiology section of the Chronic Spontaneous Urticaria (CSU) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, there are several drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies and Drug: Patients will be randomized to receive Benralizumab; AstraZeneca, SAR231893; Sanofi, CT-P39; Celltrion, Ligelizumab; Novartis Pharmaceuticals, CDX-0159; Celldex Therapeutics, LY3454738; Eli Lilly, UCB8600; UCB Biopharma, UB-221; United BioPharma, UB-221; UBP Greater China (Shanghai) Co., Ltd, GDC-0853; Genentech, Inc., KPL-716; Kiniksa Pharmaceuticals, Ltd.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,